Transforming growth factor-alpha and human cancer
- PMID: 2696564
- DOI: 10.1016/0753-3322(89)90083-8
Transforming growth factor-alpha and human cancer
Abstract
Human transforming growth factor-alpha TGF-alpha, a polypeptide growth factor which causes reversible transformation of normal cells, is composed of 50 amino acid residues, has a 30 to 40% amino acid homology to epidermal growth factor (EGF), and binds the EGF receptor. In human cancers, studies are beginning to show that TGF-alpha could serve as a tumor marker and as a marker for the malignant potential of a tumor. Thus far, the types of carcinomas with which abnormal TGF-alpha expression has been associated include liver, gastrointestinal, breast, skin, lung, brain and ovarian cancers. TGF-alpha may play a role in the processes involved with tumor initiation and tumor growth. In cell lines, TGF-alpha has been found to be associated with autocrine and paracrine types of cellular growth initiation and with increased levels of oncogene expression. In summary, the evidence concerning human TGF-alpha are that TGF-alpha could serve as a marker for human cancers and that an understanding of the basic actions of TGF-alpha could help to explain the self-sustaining nature of tumors.
Similar articles
-
Growth factors and oncogenes in human gastrointestinal carcinomas.J Cancer Res Clin Oncol. 1990;116(2):121-31. doi: 10.1007/BF01612665. J Cancer Res Clin Oncol. 1990. PMID: 2157713 Review.
-
Transforming growth factor alpha production and epidermal growth factor receptor expression in normal and oncogene transformed human mammary epithelial cells.Mol Endocrinol. 1989 Jan;3(1):203-14. doi: 10.1210/mend-3-1-203. Mol Endocrinol. 1989. PMID: 2783757
-
The effects of a constitutive expression of transforming growth factor-alpha on the growth of MCF-7 human breast cancer cells in vitro and in vivo.Mol Endocrinol. 1989 Feb;3(2):372-80. doi: 10.1210/mend-3-2-372. Mol Endocrinol. 1989. PMID: 2710138
-
Transforming growth factors in human breast cancer.Biomed Pharmacother. 1989;43(9):661-7. doi: 10.1016/0753-3322(89)90084-x. Biomed Pharmacother. 1989. PMID: 2624883
-
Expression of transforming growth factor alpha during development.Can J Physiol Pharmacol. 1988 Aug;66(8):1113-21. doi: 10.1139/y88-183. Can J Physiol Pharmacol. 1988. PMID: 3052745 Review.
Cited by
-
Azithromycin and Ceftriaxone Differentially Activate NLRP3 in LPS Primed Cancer Cells.Int J Mol Sci. 2022 Aug 22;23(16):9484. doi: 10.3390/ijms23169484. Int J Mol Sci. 2022. PMID: 36012769 Free PMC article.
-
Engineering micro oxygen factories to slow tumour progression via hyperoxic microenvironments.Nat Commun. 2022 Aug 2;13(1):4495. doi: 10.1038/s41467-022-32066-w. Nat Commun. 2022. PMID: 35918337 Free PMC article.
-
Specific humoral response in cancer patients treated with a VEGF-specific active immunotherapy procedure within a compassionate use program.BMC Immunol. 2020 Mar 14;21(1):12. doi: 10.1186/s12865-020-0338-4. BMC Immunol. 2020. PMID: 32171254 Free PMC article.
-
Antisense Oligonucleotides Targeting Angiogenic Factors as Potential Cancer Therapeutics.Mol Ther Nucleic Acids. 2019 Mar 1;14:142-157. doi: 10.1016/j.omtn.2018.11.007. Epub 2018 Nov 20. Mol Ther Nucleic Acids. 2019. PMID: 30594893 Free PMC article. Review.
-
Identification of pro- and mature brain-derived neurotrophic factor in human saliva.Arch Oral Biol. 2009 Jul;54(7):689-95. doi: 10.1016/j.archoralbio.2009.04.005. Epub 2009 May 20. Arch Oral Biol. 2009. PMID: 19467646 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
